David Marin

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression
    Sarah Marktel
    Department of Hematology, Imperial College at Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Haematologica 88:260-7. 2003
  2. doi Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 30:232-8. 2012
  3. ncbi Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
    David Marin
    Department of Haematology, Imperial College London at Hammersmith Hospital, London, United Kingdom
    Cancer 103:1850-5. 2005
  4. doi European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, United Kingdom
    Blood 112:4437-44. 2008
  5. doi Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, UK
    Br J Haematol 145:373-5. 2009
  6. doi The next questions in chronic myeloid leukaemia and their answers
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital London, UK
    Curr Opin Hematol 20:163-8. 2013
  7. doi Management of the new patient with CML in chronic phase
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK
    Curr Hematol Malig Rep 8:37-42. 2013
  8. doi Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia
    David Marin
    Hammersmith Hospital, Imperial College London, London, United Kingdom
    Hematology Am Soc Hematol Educ Program 2012:115-21. 2012
  9. doi Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, United Kingdom
    Blood 120:291-4. 2012
  10. doi Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 28:2381-8. 2010

Collaborators

Detail Information

Publications54

  1. ncbi Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression
    Sarah Marktel
    Department of Hematology, Imperial College at Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Haematologica 88:260-7. 2003
    ....
  2. doi Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 30:232-8. 2012
    ....
  3. ncbi Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
    David Marin
    Department of Haematology, Imperial College London at Hammersmith Hospital, London, United Kingdom
    Cancer 103:1850-5. 2005
    ....
  4. doi European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, United Kingdom
    Blood 112:4437-44. 2008
    ..The predictive value of some other individual criteria varied. In general, the LeukemiaNet criteria have useful predictive value, but a case could now be made for combining the categories "failure" and "suboptimal response."..
  5. doi Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, UK
    Br J Haematol 145:373-5. 2009
    ..05%; increases that never exceeded 0.05% had no predictive value. The finding of a kinase domain mutation in a patient in CCyR, though rare, also predicted for loss of CCyR...
  6. doi The next questions in chronic myeloid leukaemia and their answers
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital London, UK
    Curr Opin Hematol 20:163-8. 2013
    ..In this review, we analyze some of the topical issues in the clinical management of chronic myeloid leukaemia (CML)...
  7. doi Management of the new patient with CML in chronic phase
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK
    Curr Hematol Malig Rep 8:37-42. 2013
    ..In this paper we analyze the pros and cons of the various alternatives to imatinib and try to give some advice on the management of the newly diagnosed patient...
  8. doi Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia
    David Marin
    Hammersmith Hospital, Imperial College London, London, United Kingdom
    Hematology Am Soc Hematol Educ Program 2012:115-21. 2012
    ..The pros and cons of the various alternatives to imatinib are analyzed herein, and I try to answer the question of are we ready to abandon imatinib and, if yes, then what treatment should a patient diagnosed today receive...
  9. doi Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, United Kingdom
    Blood 120:291-4. 2012
    ..2%, 0.92%, and 0.57% for complete cytogenetic response, 3 log and 4.5 log reductions in the transcript level, respectively. The study was registered at www.clinicaltrials.gov as #NCT01460693...
  10. doi Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 28:2381-8. 2010
    ..There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence...
  11. pmc Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    Dragana Milojkovic
    Department of Haematology, Imperial College London, Du Cane Road, London W12 0NN, United Kingdom
    Haematologica 95:224-31. 2010
    ..However, it has not yet been established which of the patients in whom imatinib treatment fails are likely to benefit from therapy with second-generation tyrosine kinase inhibitors...
  12. doi Current status of imatinib as frontline therapy for chronic myeloid leukemia
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, UK
    Semin Hematol 47:312-8. 2010
    ..Here we review the current results with imatinib, the prognostic factors for response, and issues associated with long-term treatment with imatinib such as pregnancy, adherence to therapy, and complete molecular responses...
  13. pmc Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
    Dragana Milojkovic
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Blood 119:1838-43. 2012
    ..Using an intention-to-treat analysis, we have shown that the responses to second-line therapies are durable. Patients destined to fare poorly can be identified early during therapy...
  14. doi Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis
    Hugues de Lavallade
    Department of Haematology, Imperial College London, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 26:3358-63. 2008
    ..Here, we report our experience in treating patients at a single institution in a setting where all events were recorded...
  15. doi Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
    Amr R Ibrahim
    Department of Haematology, Imperial College London, London, UK
    Blood 116:5497-500. 2010
    ..Factors measurable before starting treatment with third line therapy and cytogenetic responses at 3 months can accurately predict subsequent outcome and thus guide clinical decisions...
  16. ncbi Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa
    David Marin
    Department of Haematology, Hammersmith Hospital, W12 0NN, London, UK
    Lancet 362:617-9. 2003
    ..64). Our findings suggest that cytogenetic responders obtain benefit from imatinib but patients who show no cytogenetic response should be given alternative treatment without delay. We confirmed these results in a case-matched analysis...
  17. doi Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
    Jamshid S Khorashad
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 26:4806-13. 2008
    ..Kinase domain (KD) mutations in the BCR-ABL gene are associated with resistance to imatinib in chronic myeloid leukemia (CML) but their incidence and prognostic significance in chronic phase (CP) patients without resistance are unclear...
  18. doi Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
    Amr R Ibrahim
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, United Kingdom
    Blood 117:3733-6. 2011
    ..In summary, we have shown that poor adherence is the principal factor contributing to the loss of cytogenetic responses and treatment failure in patients on long-term therapy...
  19. doi Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation
    Holger W Auner
    Centre for Haematology, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK
    Leuk Lymphoma 54:2200-4. 2013
    ..In summary, salvage AHCT2 is an effective treatment option in patients with chemosensitive relapse/progression and prolonged remission after a prior autograft...
  20. ncbi In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
    Jamshid S Khorashad
    Department of Haematology, Hammersmith Hospitals Trust and Imperial College London, London, United Kingdom
    Blood 111:2378-81. 2008
    ....
  21. doi Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
    Pratap Neelakantan
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Blood 121:2739-42. 2013
    ..In summary, early intervention strategies can be based robustly just on the transcript level at 3 months. This trial was registered at www.clinicaltrials.gov as # NCT01460693...
  22. doi EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors
    Mustafa Daghistani
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Blood 116:6014-7. 2010
    ..Our data suggest that screening for EVI-1 expression at the time of imatinib failure may predict for response to second-line TKI therapy and consequently aid clinical management...
  23. pmc Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed
    Amr R Ibrahim
    Department of Haematology, Imperial College London, London, UK
    Haematologica 96:1779-82. 2011
    ....
  24. doi A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia
    Jacob Grinfeld
    Department of Haematology, Imperial College Healthcare NHS Trust, London, UK
    Br J Haematol 163:631-9. 2013
    ..Patients lacking 8(+) and 3(-) (NN, 18%) showed the best outcomes overall. Thus, while SLC22A1 expression does not appear to affect response, alterations in its splicing or amino acid sequence may do so. ..
  25. pmc The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
    Jamshid Sorouri Khorashad
    Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom
    Haematologica 94:861-4. 2009
    ....
  26. pmc Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
    Jaspal Kaeda
    Department of Haematology, Imperial College at Hammersmith Hospital, London, UK
    Blood 107:4171-6. 2006
    ....
  27. ncbi Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation
    Eduardo Olavarria
    Haematology Department, Hammersmith Hospital, London, England
    Blood 99:3861-2. 2002
    ..This case demonstrates that imatinib mesylate can be highly effective in the management of patients who have relapses after allograft for CML...
  28. doi Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
    Hugues de Lavallade
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Blood 122:227-38. 2013
    ..These data indicate that TKIs, through off-target inhibition of kinases important in B-cell signaling, reduce memory B-cell frequencies and induce significant impairment of B-cell responses in CML. ..
  29. ncbi Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission
    Jiri Pavlu
    Department of Haematology, Imperial College at Hammersmith Hospital, Du Cane Road, London, UK
    Br J Haematol 137:423-8. 2007
    ..There were no grade III or IV non-haematological adverse effects. Grade I fatigue, hypocalcaemia and fever were common side effects. No responses were demonstrated after 6 months on the combination...
  30. doi EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure
    Katayoun Rezvani
    Department of Hematology, Imperial College, Hammersmith Hospital, Du Cane Road, London, UK
    Biol Blood Marrow Transplant 18:235-40. 2012
    ..3% for risk score 4 (intermediate, n = 42), and only 10.4% for risk scores 5-7 (high, n = 57), P = .001. We propose that the EBMT risk score can identify patients most likely to benefit from a second transplantation...
  31. doi Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation
    Paula Garland
    Department of Hematology, Imperial College London, London, UK
    Biol Blood Marrow Transplant 17:632-9. 2011
    ..These data offer novel insights into humoral and cell-mediated immunologic responses to primary H1N1 infection...
  32. doi Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia
    Letizia Foroni
    Department of Haematology, Imperial College Academic Health Science Centre, Hammersmith Campus, London, W12 ONN United Kingdom
    Am J Hematol 84:517-22. 2009
    ..The technical aspects and clinical applications of molecular monitoring will be the main focus of this article...
  33. doi Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase
    Jiri Pavlu
    Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom
    Blood 115:4018-20. 2010
    ..CML patients without comorbidities (HCT-CI score 0) with normal CRP levels (0-9 mg/L) may therefore be candidates for early allogeneic HCT after failing imatinib...
  34. doi PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase
    Juan M Alonso-Dominguez
    Centre for Haematology, Department of Medicine, Imperial College London, London, United Kingdom
    Am J Hematol 90:20-6. 2015
    ..Given the different treatments available for CML, measuring PTCH1 expression at diagnosis may help establish who will benefit best from imatinib and who is better selected for second generation TKI...
  35. doi Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements
    Valeria A S De Melo
    Department of Haematology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
    Cancer Genet Cytogenet 182:111-5. 2008
    ..1 and 22q11.2 chromosomal regions, regardless of the subsequent mechanism of chromosomal rearrangement...
  36. ncbi Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia
    Jyoti Wadhwa
    Department of Haematology, Hammersmith Hospital and Faculty of Medicine, Imperial College at Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom
    Blood 99:2304-9. 2002
    ..We conclude that survival after onset of BT has improved in recent years but is still unsatisfactory. We speculate that the combined use of STI571 with cytotoxic drugs may offer additional benefit...
  37. doi Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
    Aristeidis Chaidos
    Centre for Haematology, Faculty of Medicine, Imperial College London, London, United Kingdom
    Blood 119:5030-6. 2012
    ..In conclusion, higher doses of CD4(-) iNKT cells in PBSC grafts are associated with protection from aGVHD. This effect could be harnessed for prevention of aGVHD...
  38. ncbi Clinical decisions for chronic myeloid leukemia in the imatinib era
    John M Goldman
    Department of Haematology, Imperial College London at Hammersmith Hospital, London, UK
    Semin Hematol 40:98-103; discussion 104-13. 2003
    ..It is likely that the role of imatinib, used alone or in combination with other agents, will be more clearly defined in the near future...
  39. ncbi Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons
    Myrtle Y Gordon
    Leukaemia Research Fund Centre, Imperial College Faculty of Medicine, Hammersmith Campus, London, UK
    Br J Haematol 122:424-9. 2003
    ..01 and 0.03 respectively). We conclude that heterogeneity in the CML patient population is analogous to the constitutional diversity in normal subjects...
  40. pmc Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis
    Fabrizio Vianello
    Department of Haematology, Kennedy Institute of Rheumatology, Imperial College, London, UK
    Haematologica 95:1081-9. 2010
    ..Mesenchymal stromal cells in the bone marrow may favor the persistence and progression of leukemia by preserving the proliferation and self-renewal capacities of the malignant progenitor cells...
  41. doi BCR-ABL1 kinase domain mutations: methodology and clinical evaluation
    Mary Alikian
    Imperial Molecular Pathology Laboratory, Imperial College NHS Trust and Academic Science Centre, Hammersmith Hospital, London W12 OHS, United Kingdom
    Am J Hematol 87:298-304. 2012
    ..Advantages, disadvantages, interpretation of results, and their clinical applications are reviewed for each method...
  42. ncbi Management decisions in chronic myeloid leukemia
    John M Goldman
    Department of Haematology, Imperial College at Hammersmith Hospital, London, UK
    Semin Hematol 40:97-103. 2003
    ..Undoubtedly, the suggestions made here will require revision as we acquire further information on the utility of imatinib...
  43. doi Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma
    Ian H Gabriel
    Department of Hematology, Imperial College, London, UK
    Blood 116:2033-9. 2010
    ....
  44. doi Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed
    Lina Eliasson
    Centre for Medication Safety and Service Quality, Department of Practice and Policy, The School of Pharmacy, University of London, London, UK
    Leuk Res 35:626-30. 2011
    ..This study forms a basis on which to build future adherence research and may help to develop interventions designed to ensure that patients with CML and other cancers adhere optimally to their oral drugs treatment...
  45. ncbi Is imatinib still an acceptable first-line treatment for CML in chronic phase?
    John M Goldman
    Department of Haematology, Imperial College London, United Kingdom
    Oncology (Williston Park) 26:901-7. 2012
    ..This choice may be based primarily on considerations of cost or possible side effects...
  46. ncbi Personalized medical treatment strategies for patients with chronic myeloid leukemia
    Catherine Burton
    Imperial College School of Medicine, Department of Haematology, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK
    Expert Rev Anticancer Ther 5:343-53. 2005
    ....
  47. ncbi Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation
    Jolanta B Perz
    Department of Haematology, Hammersmith Hospital NHS Trust, Du Cane Road, W12 London, UK
    Leuk Res 31:1433-6. 2007
    ..1% in this cohort...
  48. doi Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogenetics
    Alistair G Reid
    Departments of Histopathology and Haematology, Hammersmith Hospital and Imperial College, London, UK
    Leuk Res 33:418-25. 2009
    ..Among myeloid-BC, CD34-negative cases were more often associated with trisomy-8, 17p-loss and numerical abnormalities, and the CD117-negative subset with additional copies of Ph (p<0.05)...
  49. ncbi Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
    Jane F Apperley
    Department of Haematology, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    N Engl J Med 347:481-7. 2002
    ..The tyrosine kinase inhibitor imatinib mesylate specifically inhibits ABL, PDGFR, and KIT kinases and has impressive clinical efficacy in BCR-ABL-positive chronic myeloid leukemia...
  50. pmc Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host
    Hugues de Lavallade
    Department of Haematology, Imperial College, Hammersmith Campus, 4th Floor Commonwealth Building, Du Cane Road, London W12 0NN, UK
    Haematologica 96:307-14. 2011
    ..The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies...
  51. doi Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials
    Jiri Pavlu
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College, London W12 0NN, UK
    Clin Lymphoma Myeloma 9:417-24. 2009
    ..These trials demonstrate that dasatinib offers clinical benefit to patients resistant or intolerant to imatinib, with a well-described and manageable adverse event profile...
  52. pmc FISH mapping of Philadelphia negative BCR/ABL1 positive CML
    Anna Virgili
    Molecular Cytogenetics, Academic Haematology, Royal Free and UCL Medical School, Rowland Hill Street, London, NW3 2PF, UK
    Mol Cytogenet 1:14. 2008
    ..Here we present FISH mapping data of BCR and ABL1 flanking regions and associated chromosomal rearrangements in 9 Ph negative BCR/ABL1 positive CML patients plus the cell line CML-T1...
  53. pmc KIR gene haplotype: an independent predictor of clinical outcome in MDS patients
    Kate Stringaris
    Department of Haematology, Hammersmith Hospital, Imperial College London, United Kingdom
    Blood . 2016
    ..25 [1.17-4.31], p=0.02), compared to KIR haplotype B (multiple aKIR genes). These novel findings may help to identify MDS patients with a high risk of disease progression, who would likely benefit from adoptive NK cell therapy...
  54. doi Current opinions and controversies in chronic myeloid leukaemia
    Bhuvan Kishore
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, UK
    Curr Opin Oncol 23:659-64. 2011
    ..Here we intend to focus on clinically based problems and their solution based on the evidence from literature and our experience as a centre for excellence...